CSB 2.15(1)
(1)
Paragraph (mn) of sub. (4), s. 161.14, Stats., is created to read:
(mn) Parahexyl
CSB 2.15(2)
(2) Paragraph (a) of sub. (3), s. 161.22, Stats., is repealed.
CSB 2.15(3)
(3) Paragraph (nm) of sub. (2), s. 161.20, Stats., is created to read:
(nm) Triazolam
CSB 2.15 History
History:
Cr.
Register, October, 1984, No. 346, eff. 11-1-84.
CSB 2.16
CSB 2.16
Transfer of sufentanil from schedule I to schedule II. CSB 2.16(1)(1)
Section 161.14 (2) (xg), Stats., is repealed.
CSB 2.16(2)
(2) Section 161.16 (3) (y), Stats., is created to read:
(y) Sufentanil
CSB 2.16 History
History:
Cr.
Register, October, 1984, No. 346, eff. 11-1-84.
CSB 2.17
CSB 2.17
Addition of buprenorphine to schedule V; transfer of methaqualone from schedule II to schedule I; transfer of dronabinol from schedule I to schedule II. CSB 2.17(2)(2) Paragraph (b) of s. 161.14 (5), Stats., is adopted to read:
(b) Methaqualone
CSB 2.17(3)
(3) Subsection (7) (am) of s. 161.16, Stats., is repealed.
CSB 2.17(4)
(4) Subsection (10) (a) of s. 161.16, Stats., is created to read:
(10) Hallucinogenic substances. (a) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. food and drug administration approved drug product. (Other names for dronabinol are (6a R - trans) - 6a, 7, 8, 10a - tetrahydro - 6, 6, 9 - trimethyl - 3 -pentyl-6H-dibenzo (b, d) pyran - 1 - ol, or (-) - delta - 9 - (trans) - tetrahydrocannabinol.)
CSB 2.18
CSB 2.18
Addition of 3,4-methylenedioxymethamphetamine to schedule I. Paragraph (am) of s. 161.14 (4), Stats., is created to read:
(am) 3, 4-methylenedioxymethamphetamine, commonly known as"MDMA";
CSB 2.18 History
History:
Cr.
Register, September, 1987, No. 381, eff. 10-1-87.
CSB 2.19
CSB 2.19
Additions, deletions and transfers to statutory schedules. CSB 2.19(1)(1)
Paragraph (b) of s. 161.20 (4), Stats., is created to read:
(b) Not more than 25 milligrams per dosage unit of pentazocine with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
CSB 2.19(2)
(2) Paragraph (b) of s. 161.18 (4), Stats., is repealed.
CSB 2.19(3)
(3) Paragraph (km) of s. 161.20 (2), Stats., is renumbered to read:
(mg) Prazepam;
CSB 2.19(4)
(4) Paragraph (hg) of s. 161.20 (2), Stats., is created to read:
(hg) Midazolam;
CSB 2.19(5)
(5) Paragraph (mm) of s. 161.20 (2), Stats., is created to read:
(mm) Quazepam;
CSB 2.19(6)
(6) Paragraph (km) of s. 161.18 (3), Stats., is created to read:
(km) Tiletamine and Zolazepam or any salt thereof;
CSB 2.19(7)
(7) Paragraph (a) of s. 161.16 (3), Stats., is renumbered to read:
(am) Alphaprodine;
CSB 2.19(8)
(8) Paragraph (a) of s. 161.16 (3), Stats., is created to read:
(a) Alfentanil;
CSB 2.19(9)
(9) Paragraph (rg) of s. 161.14 (2), Stats., is created to read:
(rg) MPPP 1-methyl-4-phenyl-4-propionoxypiperidine);
CSB 2.19(10)
(10) Paragraph (vg) of s. 161.14 (2), Stats., is created to read:
(vg) (PEPAP) 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine;
CSB 2.19(11)
(11) Paragraph (b) of s. 161.16 (10), Stats., is created to read:
(b) Nabilone (another name for nabilone: (+)-trans-3- (1,1-dimethylheptyl)-6, 6a, 7, 8, 10, 10a-hexahydro-1- hydroxy-6, 6-dimethyl-9H-dibenzo [b,d] pyran-9-one).
CSB 2.19(12)
(12) Subsection (2) of s. 161.14, Stats., is amended to read:
(2) Opiates. Unless specifically excepted under federal regulations or unless listed in another schedule, any of the following opiates, or their isomers, esters, ethers, salts, salts of isomers, esters of ethers, if isomers, esters, ethers, salts or salts of isomers exist within the specified chemical designation (for purposes of par. (tg) only, the term isomer includes the optical and geometric isomers):
CSB 2.19(13)
(13) Paragraph (a) of s. 161.14 (2), Stats., is renumbered to read:
(ag) Acetylmethadol;
CSB 2.19(14)
(14) Paragraph (a) of s. 161.14 (2), Stats., is created to read:
(a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
CSB 2.19(15)
(15) Paragraph (cg) of s. 161.14 (2), Stats., is created to read:
(cg) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
CSB 2.19(16)
(16) Paragraph (dg) of s. 161.14 (2), Stats., is created to read:
(dg) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl) -4-piperidinyl]-N-phenylpropanamide);
CSB 2.19(17)
(17) Paragraph (rj) of s. 161.14 (2), Stats., is created to read:
(rj) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-N-phenylpropanamide);
CSB 2.19(18)
(18) Paragraph (tg) of s. 161.14 (2), Stats., is created to read:
(tg) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1- (2-phenethyl)-4-piperidinyl]propanamide);
CSB 2.19(19)
(19) Paragraph (xm) of s. 161.14 (2), Stats., is created to read:
(xm) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide);
CSB 2.19 History
History:
Cr.
Register, February, 1988, No. 386, eff. 3-1-88.
CSB 2.20
CSB 2.20
Addition of beta-hydroxy-3-methylfentanyl to schedule I. Paragraph (er) of s. 161.14 (2), Stats., is created to read:
(er) Beta-hydroxy-3-methylfentanyl.
CSB 2.20 History
History:
Cr.
Register, July, 1989, No. 403, eff. 8-1-89.
CSB 2.21
CSB 2.21
Additions, deletions, corrections, transfers, and amendments to drug schedules. CSB 2.21(1)
(1)
Subsection (1) of s. 161.14, Stats., is amended to read:
(1) Included substances. Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in schedule I.
CSB 2.21(2)
(2) Paragraph (a) of s. 161.14 (2), Stats., is amended to read:
(a) Acetyl-alpha-methylfentany (N-[1-(1-methyl-2-phenylethyl)-4-piperidinyl]-N-phenylacetamide);
CSB 2.21(3)
(3) Paragraph (er) of s. 161.14 (2), Stats., is amended to read:
(er) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2- phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
CSB 2.21(4)
(4) Paragraph (rg) of s. 161.14 (2), Stats., is amended to read:
(rg) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
CSB 2.21(5)
(5) Paragraph (qs) of s. 161.14 (2), Stats., is amended to read:
(qs) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
piperidinyl]-N-phenylpropanamide);
CSB 2.21(6)
(6) Paragraph (tg) of s. 161.14 (2), Stats., is amended to read:
(tg) Para-fluorofentanyl (N-[1-(2-phenylethyl)-4-piperidinyl]-N-(4-fluorophenyl)propanamide);
CSB 2.21(7)
(7) Paragraph (vg) of s. 161.14 (2), Stats., is amended to read:
(vg) PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine);
CSB 2.21(8)
(8) Paragraph (xm) of s. 161.14 (2), Stats., is amended to read:
(xm) Thiofentanyl (N-[1-(2-thienyl)ethyl-4-piperidinyl]-N-
phenylpropanamide);
CSB 2.21(9)
(9) Paragraph (cd) of s. 161.14 (2), Stats., is created to read:
(cd) Alpha-methylfentanyl (N-[1-(1-methyl-2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide);
CSB 2.21(10)
(10) Paragraph (e) of s. 161.14 (3), Stats., is amended to read:
(e) Codeine-N-oxide;
CSB 2.21(11)
(11) Paragraph (j) of s. 161.14 (3), Stats., is amended to read:
(j) Etorphine, except its hydrochloride salts;
CSB 2.21(12)
(12) Paragraph (s) of s. 161.14 (3), Stats., is amended to read:
(s) Morphine-N-oxide;
CSB 2.21(13)
(13) Paragraph (a) of s. 161.14 (4), Stats., is amended to read:
